Daniel P Groom, Jennifer T Aguilan, Amanda Lopacinski, Scott J Garforth, Vern L Schramm
Journal: Proceedings of the National Academy of Sciences of the United States of America 2026;123(22):e2604770123
PMID: 42201951
The ADP-ribosylation of proteins is a versatile, reversible, posttranslational modification involved in the dynamic regulation of numerous cellular processes. Human ADP-ribosyltransferase 1 (hsART1, EC: 2.4.2.31) is a membrane-associated, GPI-anchored, mono-ADP-ribosyltransferase selective for mono-ADP ribosylation (MARylation) of L-arginine residues. Dysregulation of hsART1 activity has been shown to permit immune cell evasion in non-small cell lung cancer (NSCLC) through elevated MARylation at Arg125 of the purinergic type 2 receptor (P2X7) in P2X7-positive T cells, resulting in NAD+-induced cell death (NICD) of tumor-penetrating immune cells. With hsART1 emerging as an immunotherapy target in select cancers, there is a need to develop small-molecule inhibitors. The transition state (TS) for the MARylation of P2X7 peptide was determined from kinetic isotope effect (KIE) measurements of 3H-, 14C-, 18O-, and 15N-labeled NAD+ substrates. Quantum mechanical (QM) calculations of the reaction coordinate, mapped with experimental KIEs, identify a TS geometry consistent with a highly dissociative, asymmetric, concerted mechanism with minimal contributions from the leaving group nicotinamide (NAM) and minor contributions from the incoming L-arginine guanidinium. The absence of a normal deuterium solvent isotope effect identifies a positively charged guanidinium nucleophile, leading to a dication N-ribosyltransferase mechanism. Together with the unusual, normal 18O-O4' KIE, we identified unique charge accumulation across the oxocarbenium at the TS caused by an increased bond order between the C1'-C2', and decreased bond order between the C4'-O4' of the nicotinamide mononucleotide ribose. This is the first L-arginine-specific ADP-ribosylation TS to be characterized, a step toward the design of TS analogs.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.